The Impact of Anemia on Clinical Outcomes of Patients Above 80 Years Old Following Transcatheter Aortic Valve Replacement Authors: Besir Besir, Carl Ammoury, Alexander Egoavil, Sada Babazade, Wajeh Abuirmaileh, Osamah Badwan, Chadi Tabaja, Issam Motairek, Akiva Rosenzveig, Taha Hatab, Ali Hamam, Radwan Alkhatib, Tamari Lomaia, James J Yun, Serge C Harb, Rhonda Miyasaka, Grant W Reed, Rishi Puri, Amar Krishnaswamy, Samir R Kapadia Published: 2026 ABSTRACT Highlights•Anemia is highly prevalent among very elderly patients undergoing transcatheter aortic valve replacement and is associated with a greater burden of cardiovascular and noncardiovascular comorbidities.•Baseline anemia is associated with worse long-term clinical outcomes after transcatheter aortic valve replacement, including increased mortality and heart failure rehospitalization.•The adverse prognostic impact of anemia persists in patients over 80 years, highlighting anemia as an important risk marker and potential therapeutic target in this population.Keywords: Anemia, Frailty, Transcatheter aortic valve replacement Anemia is frequently encountered in older adults and is associated with adverse outcomes such as increased mortality and hospitalization. The population undergoing transcatheter aortic valve replacement (TAVR) is generally of advanced age, often with a median age around 80 years, making risk factors such as anemia particularly relevant. Prior studies have reported that over half of TAVR candidates are anemic, with iron deficiency identified as a contributing cause in more than 50 percent of cases.1 Although anemia is common in elderly adults in the general population, its prevalence is even higher among patients undergoing TAVR, likely reflecting not only advanced age and comorbidity burden but also mechanisms more specific to severe aortic stenosis, including acquired von Willebrand factor abnormalities and gastrointestinal bleeding from angiodysplasia. Notably, preprocedural anemia has been linked to worse long-term survival after TAVR, and moderate or severe anemia appears to independently predict higher 1-year mortality following the procedure.2 However, most existing studies have included broad age ranges, and relatively few have focused specifically on the oldest TAVR recipients, who may differ substantially in terms of frailty, comorbidity burden, and physiologic reserve.3 Despite established associations between anemia and adverse outcomes, the prognostic significance of anemia in older TAVR patients remains incompletely characterized. We therefore undertook a focused analysis of patients aged over 80 years undergoing TAVR to clarify the impact of baseline anemia on long-term outcomes in this high-risk elderly population and explore the comorbidities associated with anemia. We performed a retrospective cohort analysis of 1312 patients aged over 80 years who underwent TAVR at Cleveland Clinic between 2016 and 2020. Baseline anemia was defined according to World Health Organization criteria, with hemoglobin levels below 13 g/dL in men and below 12 g/dL in women measured before the procedure. Baseline demographics, comorbid conditions, procedural characteristics, and echocardiographic parameters were compared between patients with and without anemia. The primary outcomes were all-cause mortality and heart failure (HF) rehospitalization over a 3-year follow-up period. Time-to-event analyses were performed using Kaplan–Meier methods. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CI for the association of anemia with outcomes. For HF hospitalization, competing-risk analyses were performed using cumulative incidence functions and Fine–Gray subdistribution hazard models, with death treated as a competing event (Supplemental Figure 1). Further analysis was performed to compare patients with moderate-to-severe anemia (hemoglobin <10 g/dL) and patients with mild anemia. Of the 1312 patients included in the analysis, 698 patients (53%) met the criteria for anemia at baseline. The mean age of the overall population was 85.8 ± 4.0 years, 43% of which were females (560 patients). Patients with anemia were more likely to be older, male, and have lower body surface area. Anemic patients also had a higher prevalence of hypertension, chronic kidney disease, diabetes mellitus, and atrial fibrillation, as well as lower left ventricular ejection fraction and more frequent moderate to severe tricuspid regurgitation, compared with patients without anemia (all p < 0.05). These variables remained significant predictors of anemia in logistic regression analysis. During 3 years of follow-up, baseline anemia was associated with significantly worse clinical outcomes. The anemic group experienced higher all-cause mortality compared with the nonanemic group (HR: 1.60, 95% CI 1.26–2.03). Similarly, anemia at baseline was associated with a greater risk of HF rehospitalization over 3 years (HR: 1.61, 95% CI 1.18–2.21). Kaplan–Meier survival analysis demonstrated significantly lower 3-year survival among patients with anemia compared with those without anemia (Figure 1). In competing-risk analysis accounting for death as a competing event, baseline anemia remained associated with a higher incidence of HF hospitalization over 3 years (subdistribution HR: 1.84, 95% CI [1.36–2.50], p < 0.001) (Supplemental Figure 1). In addition, there was no difference in in-hospital bleeding and vascular complications between the 2 populations (all p-value >0.05). Patients with moderate anemia had a higher risk of 3-year mortality (HR: 1.73, 95% CI [1.28–2.34], p < 0.001) and a higher risk of 3-year HF hospitalization (HR: 1.90, 95% CI [1.28–2.81], p = 0.001). Kaplan–Meier plot for patients with anemia versus no anemia for (a) 3-year overall mortality and (b) 3-year heart failure rehospitalization. Our findings underscore that anemia identifies a particularly high-risk subset of elderly patients undergoing TAVR. The observed adverse impact of anemia on 3-year mortality and HF rehospitalization is consistent with prior literature,1,2 while extending these observations to a population that has been relatively understudied. For example, prior meta-analyses have demonstrated that anemia does not significantly affect short-term outcomes after TAVR but is associated with a meaningful increase in long-term mortality.4 In very elderly patients, the consequences of anemia may be amplified by reduced physiologic reserve, higher prevalence of frailty, and limited tolerance of hemodynamic stress. Although the association between anemia and adverse outcomes after TAVR has been described previously, our study extends these observations by focusing exclusively on patients older than 80 years, a subgroup underrepresented in prior analyses that often included broader age ranges. Anemia in TAVR patients likely reflects an accumulation of comorbid conditions and frailty, yet it may also contribute directly to adverse outcomes through diminished oxygen-carrying capacity and impaired functional recovery. Importantly, anemia is often a potentially modifiable condition. Previous studies have shown that most cases of anemia in TAVR candidates have an identifiable etiology, commonly iron deficiency. Correction of iron deficiency with intravenous iron has been shown to improve functional capacity and quality of life in patients with HF, in addition to reducing hospitalization rates.5 Whether proactive evaluation and management of anemia, including targeted iron supplementation in appropriate patients, can translate into improved post-TAVR outcomes remains uncertain and warrants further prospective investigation. Anemia may serve as a surrogate for overall illness severity in this more frail population. Nevertheless, the strength and consistency of the association observed in this very elderly cohort highlight the importance of recognizing anemia as a meaningful risk marker. Identifying and addressing reversible causes of anemia before and after TAVR may represent an opportunity to improve clinical outcomes in this growing and vulnerable patient population. Review Statement The review of this manuscript was managed by Guest Editor Harold Dauerman, MD. Ethics Statement This study was approved by the Institutional Review Board (IRB). Funding The authors have no funding to report. Disclosure Statement The authors report no conflict of interest. Guest Editor: Harold Dauerman, MD Footnotes Supplemental data for this article can be accessed on the publisher’s website. Supplementary Material Supplemental Figure 1 References Associated Data Supplementary Materials Supplemental Figure 1